Protein Kinase CK2 Cellular Function in Normal and Disease States, 2015
Advances in Biochemistry in Health and Disease Series, Vol. 12

Protein kinase CK2 (formerly casein kinase II or 2) is known to play a critical role in the control of cell growth and cell death and is thus intimately involved in the development of cancer. More specifically, CK2 has been found to be elevated in all cancers examined. While CK2 levels are known to be high in proliferating normal cells, CK2 has also been found to be a potent suppressor of apoptosis and is a link to the cancer cell phenotype, which is characterized by deregulation of both cell proliferation and cell death. Indeed, it would appear that CK2 impacts many of the hallmarks of cancer and it has now gained considerable attention as a potential target for cancer therapy. Protein Kinase CK2 and Cellular Function in Normal and Disease States increases knowledge of the role of CK2 in the development of cellular dysfunction and emphasizes that this protein may serve as a target of drug development for improved cancer therapy. In addition, it is a handy tool that provides cancer researchers, graduate students, and all scientists involved in CK2 research with one main source for the latest advances in CK2 research. ?

Part I: Regulation and Structure-Function Studies of CK2 1. Yeast Asf1 protein as modulator of protein kinase CK2 activity Andrea Baier, Ewa Alikowska and Ryszard Szyszka 2. Impressions from the conformational and configurational space captured by protein kinase CK2 Jennifer Hochscherf, Alexander Schnitzler, Olaf-Georg Issinger and Karsten Niefind 3. Structural basis of CK2 regulation by autoinhibitory oligomerization Graziano Lolli and Roberto Battistutta 4. Maize RNA binding protein ZmTGH: a new partner for CK2β1 regulatory subunit Isabel Cristina Vélez-Bermúdez and Marta Riera Part II: CK2 Control of Organismal and Cellular Functions 5. CK2 in Organ Development, Physiology, and Homeostasis Charina E. Ortega, Lawrence Prince-Wright, and Isabel Dominguez 6. Protein kinase CK2, a window into the post-translational regulation of the E(spl)/HES repressors from invertebrates and vertebrates Adam T. Majot, Tyler R. Sizemore, Mohna Bandyopadhyay, Lucas M. Jozwick and Ashok P. Bidwai 7. Tissue specific functions and regulation of protein kinase CK2 Sabrina Welker, Christina Servas, Meng Rui, Claudia Götz and Mathias Montenarh 8. CK2 function in the regulation of Akt pathway Cristina Girardi and Maria Ruzzene 9. Cellular zinc signalling is triggered by CK2 Thirayost Nimmanon and Kathryn M. Taylor 10. CK2 – A global regulator of cell death Janeen H. Trembley, Fatima Qaiser, Betsy T. Kren, Khalil Ahmed 11. Protein Kinase CK2: Systematic Relationships with Other Post-Translational Modifications David W. Litchfield and Laszlo Gyenis 12. Role for protein kinase CK2 on cell proliferation: Assessing CK2 complex components in the nucleus during the cell cycle progression Miwako Kato Homma, Takeshi Shibata, Toshiyuki Suzuki, Masato Ogura, Hiroko Kozuka-Hata, Masaaki Oyama, and Yoshimi Homma 13. “Genuine” casein kinase: the false sister of CK2 that phosphorylates secreted proteins at S-x-E/pS motifs Elena Tibaldi, Giorgio Arrigoni, Giorgio Cozza, Luca Cesaro, Lorenzo A. Pinna Part III: Function of CK2 in Cancer and its Therapeutic Targeting 14. Dysregulated expression of Protein kinase CK2 in Renal cancer Caroline Roelants, Sofia Giacosa, Eve Duchemin-Pelletier, Anne McLeer-Florin, Céline Tisseyre, Cédric Aubert, Pierre Champelovier, Jean Boutonnat, Jean Luc Descotes, Jean-Jacques Rambeaud, Valentin Arnoux, Jean-Alexandre Long, Dominique Pasquier, Mathieu Laramas, Maysoun Kassem, Laurence David-Boudet, Laure Schoutteten, Benoit Bestgen, Catherine Pillet, Claude Cochet, Odile Filhol 15. Protein Kinase CK2 and Dysregulated Oncogenic Inflammatory Signaling Pathways Etty N. Benveniste, G. Kenneth Gray and Braden C. McFarland 16. CIGB-300: A promising anti-Casein Kinase 2 (CK2) peptide for cancer targeted therapy Silvio E. Perea, Yasser Perera, Idania Baladrón, Lidia González, Fernando Benavent, Hernán G. Fariña, Idrián García, Arielis Rodríguez, Vilcy Reyes, Yanelda García, Roberto Gómez, Daniel F. Alonso, Carmen Valenzuela 17. Targeting CK2 for Cancer Therapy Using a Nanomedicine Approach Khalil Ahmed, Gretchen Unger, Betsy T. Kren, Janeen H. Trembley Part IV: Studies Involving CK2 Small Molecule Inhibitors 18. Screening of DTP compound libraries for CK2 inhibitors with focus on natural products Tine D. Rasmussen, Barbara Guerra and Olaf-Georg Issinger 19. CK2 inhibitors and the DYRK family protein kinases Yoshihiko Miyata 20. Sensitivity of protein kinase CK2 to ATP/GTP and specific inhibitors depends on complexity of interacting proteins Andrea Baier and Ryszard Szyszka